Image of Navid Madani

Navid Madani, Ph.D.

617-632-3994

Navid Madani, PhD, is a Senior Scientist in Dana-Farber Cancer Institute's Department of Cancer Immunology and Virology, with appointments at Harvard Medical School in the Departments of Microbiology and Global Health and Social Medicine. Currently, she is the principal investigator on a study that is optimizing the application of a CD4-mimetic small-molecule inhibitor of HIV-1 infection as topical microbicides. Madani has applied a deep knowledge of research and scientific-based approaches to public health projects in the areas of cancer and infectious diseases in the MENA region. The SHE Center was born out of her past decade of work in the region — bringing together crucial stakeholders within key populations.

Madani’s research emphasizes HIV/AIDS, drug discovery, and the development of a woman-controlled microbicide to halt HIV transmission. She uses a multidisciplinary approach to find preventive measures to inhibit HIV-1 transmission. Her studies have led to the biochemical characterization of two classes of small molecules that bind HIV-1 gp120 and inhibit HIV-1 entry.

Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.
Authors: Authors: Choi WT, Tian S, Dong CZ, Kumar S, Liu D, Madani N, An J, Sodroski JG, Huang Z.
J Virol
View full abstract on Pubmed
Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
Authors: Authors: Xiang SH, Farzan M, Si Z, Madani N, Wang L, Rosenberg E, Robinson J, Sodroski J.
J Virol
View full abstract on Pubmed
Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins.
Authors: Authors: Si Z, Madani N, Cox JM, Chruma JJ, Klein JC, Schön A, Phan N, Wang L, Biorn AC, Cocklin S, Chaiken I, Freire E, Smith AB, Sodroski JG.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.
Authors: Authors: Madani N, Perdigoto AL, Srinivasan K, Cox JM, Chruma JJ, LaLonde J, Head M, Smith AB, Sodroski JG.
J Virol
View full abstract on Pubmed
Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
Authors: Authors: Biorn AC, Cocklin S, Madani N, Si Z, Ivanovic T, Samanen J, Van Ryk DI, Pantophlet R, Burton DR, Freire E, Sodroski J, Chaiken IM.
Biochemistry
View full abstract on Pubmed
Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.
Authors: Authors: LaBonte JA, Madani N, Sodroski J.
J Virol
View full abstract on Pubmed
Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1.
Authors: Authors: Madani N, Millette R, Platt EJ, Marin M, Kozak SL, Bloch DB, Kabat D.
J Virol
View full abstract on Pubmed